Tempus AI, Inc. TEM

What this company does

Tempus AI, Inc. operates five laboratories that provide NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests. As of December 31, 2025, it had more than 3,800 employees, of which 1,232 were technical and were engaged in product and engineering, and research and development. Its products are organized under two product lines: Diagnostics, which comprises its Oncology and Hereditary testing businesses, and Data and applications, which includes its Insights, Next, Trials and Algos businesses. Within Diagnostics, its primary focus is cancer, offering a suite of tests for treatment purposes referred to as its Oncology tests, and a suite of hereditary tests acquired through Ambry, referred to as its Hereditary tests. Its Data and applications product line facilitates drug discovery and development for life sciences companies through multiple products, including Insights, Trials, Next and Algos. It was founded by Eric Lefkofsky under the name Bioin, LLC in Delaware in August 2015, converted to a Delaware corporation later that year as Bioin, Inc., and later changed its name to Tempus Health, Inc. in 2015, to Tempus Labs, Inc. in 2016, and to Tempus AI, Inc. in 2023.

Written from the business description in Tempus AI, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.